A pioneeer in the arena of extrahepatic oligonucleotide delivery. Trasir Therapeutics had been developing an oligonucleotide delivery platform for delivery of short interfering RNA and other therapeutic RNA payloads to sites outside the liver. In June 2021 it was announced that the firm had been acquired by Auris - shortly after renamed as Altamira Therapeutics (NASDAQ: CYTO) - a firm HQ in Hamilton, Bermuda with its main operations in Basel, Switzerland. Dedicated to developing therapeutics addressing important unmet medical needs, AltaMira is indicated as active in three areas: (1) RNA therapeutics for extrahepatic therapeutic targets (OligoPhore⢠/ SemaPhore⢠platforms; preclinical), (2) nasal sprays for protection against airborne viruses and allergens (Bentrioâ¢; commercial) or the treatment of vertigo (AM-125; Phase 2) and (3) the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Pha
